OBJECTIVES
Evidence suggests inflammation is associated with cognitive impairment, but
previous epidemiological studies have reported conflicting results.
DESIGN
Prospective population-based cohort.
SETTING
Epidemiology of Hearing Loss Study participants.
PARTICIPANTS
Individuals without cognitive impairment in 1998–2000 (N =
2,422; 1,947 with necessary data).
MEASUREMENTS
Cognitive impairment (Mini-Mental State Examination score <24 or diagnosis
of dementia) was ascertained in 1998–2000, 2003–2005, and 2009–
2010. Serum C-reactive protein (CRP) and interleukin-6 (IL-6) were measured in
1988–1990, 1998–2000, and 2009–2010; tumor necrosis factor-alpha
was measured from 1998–2000.
RESULTS
Participants with high CRP in 1988–1990 and 1998–2000 had lower
risk of cognitive impairment than those with low CRP at both time points (hazard ratio
(HR) = 0.46, 95% confidence interval (CI) = 0.26–0.80).
Risk did not differ according to 10-year IL-6 profile or baseline inflammation category
in the whole cohort. In sensitivity analyses restricted to statin nonusers, those with
high IL-6 at both times had greater risk of cognitive impairment than those with low
IL-6 at both times (HR = 3.35, 95% CI = 1.09–10.30). In
secondary analyses, each doubling of IL-6 change over 20 years was associated with
greater odds of cognitive impairment in 2009–2010 in the whole cohort (odds
ratio (OR) = 1.40, 95% CI = 1.04–1.89), whereas a
doubling of CRP change over 20 years was associated with cognitive impairment only in
statin nonusers (OR = 1.32, 95% CI = 1.06–1.65).
CONCLUSION
With data collected over 20 years, this study demonstrated greater likelihood
of cognitive impairment in individuals with repeated high or increasing IL-6. The
inconsistent CRP findings may reflect effects of statin medications, survival effects,
or adverse effects associated with chronically low CRP. Further studies of long-term
inflammation and cognitive impairment are needed.